Periodontitis is a chronic inflammatory disease of the supporting structures of the teeth and represents one of the most common oral health challenges worldwide. Current treatment strategies rely heavily on mechanical debridement and, in severe cases, systemic or local antibiotics. These approaches, while effective, often face limitations such as patient compliance, recurrence, and growing concerns regarding antimicrobial resistance.
A novel approach is offered by a muco-adhesive gel formulation containing the 2FX excipient. Applied directly onto inflamed or infected gingival tissue, the gel adheres to the mucosal surface and forms a transparent biofilm barrier. This layer clusters and neutralizes pathogenic bacteria locally, thereby reducing microbial load and inflammatory response at the site of disease activity.
Key advantages of this application include:
-
Targeted action: direct delivery at the site of infection ensures high local efficacy.
-
Barrier protection: pathogenic microbes are blocked before they can further colonize or damage gingival tissue.
-
Adjunct to standard care: enhances conventional periodontal therapy without reliance on antibiotics.
-
Evidence-based efficacy: supported by clinical trials demonstrating safety and effectiveness.
-
Flexible supply model: available as raw gel material under license, enabling dental and OTC companies to incorporate it into their own branded tubes or applicators.
By integrating 2FX into oral care formulations, periodontitis management can progress beyond symptom control towards a preventive and non-antibiotic strategy, aligning with the broader goal of sustainable oral healthcare.
